All News

Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.

As pharmacists’ role in the health of communities continues to grow, it becomes even more critical for pharmacists to be armed with advanced technology when providing drug analysis.

All individuals who received second-line chemotherapy regimens met the PFS2 endpoint and all but 1 individual had died at time of data cutoff, according to a presentation at 2022 ASCO Annual Meeting.

Pharmacies can help bring inequities plaguing health care systems to an end to ensure the COVID-19 pandemic does not follow trends of inequity experienced in the HIV pandemic.

Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.

Famvir, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for adults patients who are immunocompetent with herpes labialis (cold sores); treatment of recurrent episodes of genital herpes; and treatment of recurrent episodes, suppressive therapy of recurrent episodes and herpes zoster (shingles).

Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.

Biomarker positive patients were randomized to maintenance rucaparib 600 mg or matched placebo within 10 weeks of completing PBC until disease progression.

In light of the growing numbers of students opting for post-graduate trainings, colleges and schools of pharmacy may want to consider offering electives geared toward exposing students to post-graduate career possibilities and provide guidance toward success.

Findings of the phase 2 cohort and the phase 1b cohort of the KRYSTAL-1 study are being presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeding with a once-weekly prophylactic dosing.

The researchers noted that the objective of the study was to assess the trends of 1L PARPi maintenance treatment uptake and PFS of patients with newly diagnosed AOC.

New results from the ATHENA-MONO trial investigating the use of rucaparib in patients with ovarian cancer show promise.

The trial achieved a complete remission rate of 39.4%, which researcher Michael Dickinson, MBBS, DMedSci, called "remarkable."

Circulating tumor DNA tests could someday replace CT scans for cancer management, according to Bruce Feinberg, DO.

Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions, discussed how a cancer diagnosis and treatment can impact patients’ mental health.

Pharmacy Times spoke with Amila Patel, PharmD, chief clinical officer at Navigating Cancer, to learn about digital health solutions in oncology and what she sees for the future of these solutions.

Trastuzumab deruxtecan shows superior and clinically meaningful progression-free survival and overall survival benefit in patients with HER2-low unresectable and/or metastatic breast cancer with hormone receptor-positive or negative disease.

Three-year follow-up analysis shows that Gilead’s car T-cell therapy induced high rates of durable response and a median overall survival of 46.6 months.

Sacituzumab govitecan-hziy (Trodelvy) found to lower the risk of disease progression or death by 34% in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Kelly McAuliff, PharmD, BCOP, CSP, spoke about research into the impacts of the COVID-19 pandemic on oral oncolytic adherence, particularly for patients with ovarian cancer, prostate cancer, or chronic myelogenous leukemia.

Both patients and providers should recognize the benefits of early referrals to palliative care.

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

With a median follow-up of 90 months, individuals receiving palbociclib in combination with letrozole had numerically longer OS compared to placebo, but it was not deemed statistically significant.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.